Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Operations (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Cash from Operations for 3 consecutive years, with 24046000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Cash from Operations fell 52.44% year-over-year to 24046000.0, compared with a TTM value of 100148000.0 through Dec 2021, down 92.05%, and an annual FY2024 reading of 62303000.0, up 6.62% over the prior year.
  • Cash from Operations was 24046000.0 for Q4 2021 at Black Diamond Therapeutics, up from 26482000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5000000.0 in Q2 2019 and bottomed at 26482000.0 in Q3 2021.
  • Average Cash from Operations over 3 years is 14747333.33, with a median of 12526500.0 recorded in 2020.
  • The sharpest move saw Cash from Operations crashed 171.34% in 2020, then tumbled 52.44% in 2021.
  • Year by year, Cash from Operations stood at 7486000.0 in 2019, then crashed by 110.71% to 15774000.0 in 2020, then crashed by 52.44% to 24046000.0 in 2021.
  • Business Quant data shows Cash from Operations for BDTX at 24046000.0 in Q4 2021, 26482000.0 in Q3 2021, and 25165000.0 in Q2 2021.